TRANQUIS THERAPEUTICS
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction th... at has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.
TRANQUIS THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2016-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.tranquis.com
Total Employee:
11+
Status:
Active
Contact:
(650) 684-8950
Email Addresses:
[email protected]
Total Funding:
30 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Content Delivery Network LetsEncrypt
Similar Organizations
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Idenix Pharmaceuticals
Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Correlation Ventures
Correlation Ventures investment in Series A - Tranquis Therapeutics
Vivo Capital
Vivo Capital investment in Series A - Tranquis Therapeutics
Remiges Ventures
Remiges Ventures investment in Series A - Tranquis Therapeutics
SR One
SR One investment in Series A - Tranquis Therapeutics
Hillsborough Venture
Hillsborough Venture investment in Series A - Tranquis Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-01 | Tranquis Therapeutics Strengthens Leadership Team with Additions of Janet Hurt, MPH, as SVP of Clinical Evidence Generation and Faisal Shawwa, MBA, as SVP of Finance |
Official Site Inspections
http://www.tranquis.com Semrush global rank: 7.12 M Semrush visits lastest month: 890
- Host name: 210.252.154.104.bc.googleusercontent.com
- IP address: 104.154.252.210
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Tranquis Therapeutics"
About - Tranquis
Built on the groundbreaking immuno-neurology research of our scientific founder, Dr. Edgar Engleman, and his team at Stanford, Tranquis is focused on the discovery and development of …See details»
Tranquis Therapeutics - Crunchbase Company Profile …
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place …See details»
Tranquis
Exciting culture We pride ourselves in creating a culture and environment filled with energy, a shared purpose and fun. We bring passion, determination and focus to everything we do, encouraging innovation, teamwork and …See details»
Tranquis Therapeutics, Inc. | LinkedIn
Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming ...See details»
Tranquis Therapeutics Company Profile 2024: …
Correlation Ventures, Hillsborough Venture, Remiges Ventures, Vivo Capital, and SR One Capital Management have invested in Tranquis Therapeutics. Who are Tranquis Therapeutics’s competitors? Atalanta Therapeutics , Vertex …See details»
Tranquis Therapeutics Inc. - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Tranquis is …See details»
Tranquis Therapeutics - VentureRadar
"Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel …See details»
Tranquis Therapeutics Launches with $30 Million Series …
Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. For more information, visit www.tranquis.com. …See details»
Tranquis Therapeutics - Craft
Tranquis Therapeutics is a company that develops a technology intended to remove brain myeloid cells associated with the disease. Its technology helps in altering a variety of brain cell-related …See details»
Tranquis
Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis -Tranquis plans to start a Phase 2 trial in people living with ALS …See details»
Tranquis Therapeutics Announces Successful Completion of Phase …
Tranquis plans to start a Phase 2 trial in ALS by the end of 2022 ... Source: Tranquis.com European organization for Professionals and Patients with ALS (EUpALS) ivzw Registered …See details»
Tranquis Therapeutics Company Profile: Overview and Full News …
Tranquis Therapeutics, Inc. will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at the 9th Aging Research and Drug Discovery meeting …See details»
Tranquis Therapeutics Granted FDA Orphan Drug ... - Business Wire
Jun 21, 2022 “The orphan drug designation is an important regulatory milestone for Tranquis, further validating our efforts to develop TQS-168, an orally administered compound that …See details»
Tranquis Therapeutics Announces Initiation of Phase 1 Study of …
Dec 8, 2021 Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, …See details»
Tranquis
About Tranquis Therapeutics: Tranquis Therapeutics is a clinical stage biotech company based in the SF Bay Area. Tranquis discovers and develops innovative medicines with the potential to …See details»
Tranquis Launches with Novel Approach to Neurodegenerative …
Jul 9, 2020 With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through …See details»
Tranquis
Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. For …See details»
Tranquis Therapeutics Launches with $30 Million Series A Funding …
Jul 9, 2020 Tranquis’ Chief Business Officer, Titus Plattel, MSc, MBA has 25 years of experience leading life sciences organizations in operations, corporate development, and product planning …See details»
Science - Tranquis
Restoring cell energy metabolism, mitochondrial and lysosomal health Our unique scientific approach is based on our ability to identify drug candidates capable of reprogramming …See details»